Tom Keeley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tom Keeley has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
Rafael Alfonso-Cristancho
Global Real-World Evidence and Health Outcomes Research, GSK, Collegeville, PA, USA
3 shared publicationsAdam Gater
Patient-Centered Outcomes, Adelphi Values, Bollington, Cheshire, UK
2 shared publicationsAmanda Lopuski
GSK, Collegeville, USA
2 shared publications- Jessica Flynn
Patient-Centered Outcomes, Adelphi Values, Bollington, UK
2 shared publications John H. Powers
George Washington University School of Medicine, Washington, USA
2 shared publicationsKatie Forde
Patient-Centered Outcomes, Adelphi Values, Bollington, Cheshire, UK
2 shared publications
Latest Publications
- Open Access
- 17 October 2026
- Published by Elsevier in Advances in Patient-Reported Outcomes
- Vol. 2 (4)
Value of in-trial interviews to explore meaningful change and score interpretation for patient-reported outcome measures: DIA roundtable discussion
- 17 October 2026
- Published by Elsevier in Advances in Patient-Reported Outcomes
- Vol. 2 (4)
Open AccessValue of in-trial interviews to explore meaningful change and score interpretation for patient-reported outcome measures: DIA roundtable discussion
- Open Access
- 28 May 2026
- Published by Springer Nature in Journal of Patient-Reported Outcomes
- Vol. 10 (1)
Asthma daytime and nighttime symptom diaries: content validity and qualitative exploration of meaningful change in patients with moderate-to-severe asthma
Background: Asthma symptom severity can be assessed using the Asthma Daytime and Nighttime Symptom Diaries (ADSD and ANSD), which provide an accurate and standardized patient-reported option for symptom assessment during different periods of the day (i.e. daytime and nighttime), as these can vary significantly. Earlier development and validation work for the ADSD and ANSD was conducted in a broad (i.e. ranging from mild to severe) asthma population, and a US Food and Drug Administration qualification statement noted the need for further evaluation of their measurement properties, including content validity. The current study, which builds upon earlier work, was designed to ensure that the ADSD and ANSD are content-valid in patients with moderate-to-severe asthma. Methodology: Qualitative semi-structured concept elicitation and cognitive debriefing interviews were conducted in adults with moderate-to-severe asthma to investigate understanding of ADSD and ANSD instructions, items, recall period, response options, and concept relevance. Changes in total and item scores that were meaningful to patients were explored. General feedback on the measures was also requested. Results: The study recruited 15 patients with moderate-to-severe asthma. Content validity findings were consistent with previous studies, supporting inclusion of six core symptoms (i.e. wheezing, cough, difficulty breathing, shortness of breath, chest tightness and chest pain) as items in the ADSD and ANSD that occur during a typical day or night and impact upon patient well-being and functioning. A high level of understanding and relevance of the diary items to patients was demonstrated; instructions were confirmed to be easy to follow. In supportive analyses, meaningful levels of improvement on the ADSD and ANSD ranged from 0.5 to 3.5 and 0.2 to 5.0 respectively. Meanwhile, meaningful levels of worsening on the ADSD and ANSD ranged from 1.0 to 5.8 and 0.5 to 6.7 respectively. Conclusions: The ADSD and ANSD are content-valid measures for the measurement of daytime and nighttime symptoms and their severity in patients with moderate-to-severe asthma. Additional confirmatory studies are required to confirm the psychometric properties of the ADSD and ANSD in a moderate-to-severe population and to quantitatively estimate the threshold for meaningful improvement and worsening.
- 28 May 2026
- Published by Springer Nature in Journal of Patient-Reported Outcomes
- Vol. 10 (1)
Open AccessAsthma daytime and nighttime symptom diaries: content validity and qualitative exploration of meaningful change in patients with moderate-to-severe asthma
Background: Asthma symptom severity can be assessed using the Asthma Daytime and Nighttime Symptom Diaries (ADSD and ANSD), which provide an accurate and standardized patient-reported option for symptom assessment during different periods of the day (i.e. daytime and nighttime), as these can vary significantly. Earlier development and validation work for the ADSD and ANSD was conducted in a broad (i.e. ranging from mild to severe) asthma population, and a US Food and Drug Administration qualification statement noted the need for further evaluation of their measurement properties, including content validity. The current study, which builds upon earlier work, was designed to ensure that the ADSD and ANSD are content-valid in patients with moderate-to-severe asthma. Methodology: Qualitative semi-structured concept elicitation and cognitive debriefing interviews were conducted in adults with moderate-to-severe asthma to investigate understanding of ADSD and ANSD instructions, items, recall period, response options, and concept relevance. Changes in total and item scores that were meaningful to patients were explored. General feedback on the measures was also requested. Results: The study recruited 15 patients with moderate-to-severe asthma. Content validity findings were consistent with previous studies, supporting inclusion of six core symptoms (i.e. wheezing, cough, difficulty breathing, shortness of breath, chest tightness and chest pain) as items in the ADSD and ANSD that occur during a typical day or night and impact upon patient well-being and functioning. A high level of understanding and relevance of the diary items to patients was demonstrated; instructions were confirmed to be easy to follow. In supportive analyses, meaningful levels of improvement on the ADSD and ANSD ranged from 0.5 to 3.5 and 0.2 to 5.0 respectively. Meanwhile, meaningful levels of worsening on the ADSD and ANSD ranged from 1.0 to 5.8 and 0.5 to 6.7 respectively. Conclusions: The ADSD and ANSD are content-valid measures for the measurement of daytime and nighttime symptoms and their severity in patients with moderate-to-severe asthma. Additional confirmatory studies are required to confirm the psychometric properties of the ADSD and ANSD in a moderate-to-severe population and to quantitatively estimate the threshold for meaningful improvement and worsening.
- Open Access
- 20 May 2026
- Published by Springer Nature in Journal of Patient-Reported Outcomes
- Vol. 10 (1)
Validity, reliability, and longitudinal measurement properties of the Asthma Daytime and Nighttime Symptom Diaries in patients with moderate-to-severe asthma
Background: The Asthma Daytime and Nighttime Symptom Diaries (ADSD and ANSD) were developed to provide an accurate and standardized instrument for assessing patient-reported severity of asthma symptoms. While previous evidence supports the content validity and cross-sectional measurement properties of the ADSD and ANSD, the US Food and Drug Administration (FDA) qualification statement for these tools recommended further evaluation of their longitudinal measurement properties and the interpretation of within-patient meaningful change (WPMC). Therefore, two complementary studies were designed to assess cross-sectional and longitudinal measurement properties and estimate thresholds for WPMC for the ADSD/ANSD in patients with moderate-to-severe asthma, responding to measurement gaps identified in the FDA statement. Methodology: Quantitative evaluation of ADSD/ANSD (score range 0 to 10) measurement properties was performed in a real-world observational study (RWS; ≥16 years old; moderate-to-severe asthma) and a randomized controlled trial (RCT; ≥12 years old; severe asthma with type 2 inflammation). Cross-sectional and longitudinal measurement properties were assessed and WPMC thresholds estimated. Results: A total of 576 patients with moderate-to-severe asthma were recruited across both studies. The RWS ( n = 241) and RCT ( n = 335) both found the ADSD/ANSD to have high internal consistency and test-retest reliability with Cronbach’s α-coefficients ≥0.94 and intraclass correlation coefficients ≥0.90. Evidence in support of the unidimensional scoring solution for both the ADSD and ANSD was established via confirmatory factor analysis across timepoints and studies, and evidence of construct validity was demonstrated via convergent and known-groups validity testing. In the blinded RCT analysis, the threshold for WPMC was estimated at 1.2 for the ADSD and 1.5 for the ANSD. In the RWS, the WPMC threshold for within-patient improvement was estimated to be from 0.6 to 1.3 for ADSD and from 0.8 to 1.4 for ANSD across 6- and 10-week intervals. Conclusions: This study directly addresses the evidence gaps identified by the FDA, demonstrating that the ADSD and ANSD are reliable and valid tools for the measurement of daily symptoms in patients with moderate-to-severe asthma, and are capable of detecting WPMC. Values derived from the RCT analysis support a recommendation for thresholds for meaningful within-patient change of 1.2 and 1.5 for the ADSD and ANSD, respectively. Clinical trial registration: GSK ID: 217640; NCT04719832.
- 20 May 2026
- Published by Springer Nature in Journal of Patient-Reported Outcomes
- Vol. 10 (1)
Open AccessValidity, reliability, and longitudinal measurement properties of the Asthma Daytime and Nighttime Symptom Diaries in patients with moderate-to-severe asthma
Background: The Asthma Daytime and Nighttime Symptom Diaries (ADSD and ANSD) were developed to provide an accurate and standardized instrument for assessing patient-reported severity of asthma symptoms. While previous evidence supports the content validity and cross-sectional measurement properties of the ADSD and ANSD, the US Food and Drug Administration (FDA) qualification statement for these tools recommended further evaluation of their longitudinal measurement properties and the interpretation of within-patient meaningful change (WPMC). Therefore, two complementary studies were designed to assess cross-sectional and longitudinal measurement properties and estimate thresholds for WPMC for the ADSD/ANSD in patients with moderate-to-severe asthma, responding to measurement gaps identified in the FDA statement. Methodology: Quantitative evaluation of ADSD/ANSD (score range 0 to 10) measurement properties was performed in a real-world observational study (RWS; ≥16 years old; moderate-to-severe asthma) and a randomized controlled trial (RCT; ≥12 years old; severe asthma with type 2 inflammation). Cross-sectional and longitudinal measurement properties were assessed and WPMC thresholds estimated. Results: A total of 576 patients with moderate-to-severe asthma were recruited across both studies. The RWS ( n = 241) and RCT ( n = 335) both found the ADSD/ANSD to have high internal consistency and test-retest reliability with Cronbach’s α-coefficients ≥0.94 and intraclass correlation coefficients ≥0.90. Evidence in support of the unidimensional scoring solution for both the ADSD and ANSD was established via confirmatory factor analysis across timepoints and studies, and evidence of construct validity was demonstrated via convergent and known-groups validity testing. In the blinded RCT analysis, the threshold for WPMC was estimated at 1.2 for the ADSD and 1.5 for the ANSD. In the RWS, the WPMC threshold for within-patient improvement was estimated to be from 0.6 to 1.3 for ADSD and from 0.8 to 1.4 for ANSD across 6- and 10-week intervals. Conclusions: This study directly addresses the evidence gaps identified by the FDA, demonstrating that the ADSD and ANSD are reliable and valid tools for the measurement of daily symptoms in patients with moderate-to-severe asthma, and are capable of detecting WPMC. Values derived from the RCT analysis support a recommendation for thresholds for meaningful within-patient change of 1.2 and 1.5 for the ADSD and ANSD, respectively. Clinical trial registration: GSK ID: 217640; NCT04719832.
- Open Access
- 20 December 2024
- Published by Springer Nature in Journal of Patient-Reported Outcomes
- Vol. 8 (1) , 152
Chronic rhinosinusitis with nasal polyps (CRSwNP) symptom verbal response scales: content validity testing for use in adults with CRSwNP
Background: PRO measures of symptoms in clinical trials have historically utilized visual and numerical scales but verbal descriptors may make it easier for patients to clearly differentiate between response options. This study assessed content validity and meaningful change in five verbal response scales (VRSs) used to assess chronic rhinosinusitis with nasal polyp (CRSwNP) symptom severity. Methodology: This qualitative, semi-structured interview study recruited adults from the US, Germany, and China with confirmed moderate-to-severe CRSwNP. Interviews included a concept elicitation section, where participants were asked about their experience of living with CRSwNP including symptoms and health-related quality-of-life impacts, and a cognitive debriefing section, where participants were debriefed and participant understanding and real-life relevance of the CRSwNP symptom VRS content were assessed. Interview transcripts were qualitatively analyzed using thematic analysis methods. Results: Among the 24 participants interviewed, the most frequently reported CRSwNP symptoms were nasal obstruction, runny nose, mucus in the throat, loss of smell and facial pain/pressure. Participants demonstrated good understanding of the CRSwNP symptom VRS instructions, items, recall period, and response options. The five CRSwNP symptom VRS items were relevant to the majority of participants’ experience of CRSwNP. At the item level, a one-category within-person improvement was the level most frequently reported by participants to be a meaningful change. Conclusion: The CRSwNP symptom VRSs assess relevant and bothersome symptoms experienced by patients with moderate-to-severe CRSwNP, supporting content validity of this measure. The findings of this study provided preliminary insights into meaningful change in the VRS. Further quantitative assessment of meaningful change is needed, and psychometric evaluation of the CRSwNP symptom VRSs will be required to evaluate their appropriateness for assessment of clinical trial endpoints in patients with CRSwNP.
- 20 December 2024
- Published by Springer Nature in Journal of Patient-Reported Outcomes
- Vol. 8 (1) , 152
Open AccessChronic rhinosinusitis with nasal polyps (CRSwNP) symptom verbal response scales: content validity testing for use in adults with CRSwNP
Background: PRO measures of symptoms in clinical trials have historically utilized visual and numerical scales but verbal descriptors may make it easier for patients to clearly differentiate between response options. This study assessed content validity and meaningful change in five verbal response scales (VRSs) used to assess chronic rhinosinusitis with nasal polyp (CRSwNP) symptom severity. Methodology: This qualitative, semi-structured interview study recruited adults from the US, Germany, and China with confirmed moderate-to-severe CRSwNP. Interviews included a concept elicitation section, where participants were asked about their experience of living with CRSwNP including symptoms and health-related quality-of-life impacts, and a cognitive debriefing section, where participants were debriefed and participant understanding and real-life relevance of the CRSwNP symptom VRS content were assessed. Interview transcripts were qualitatively analyzed using thematic analysis methods. Results: Among the 24 participants interviewed, the most frequently reported CRSwNP symptoms were nasal obstruction, runny nose, mucus in the throat, loss of smell and facial pain/pressure. Participants demonstrated good understanding of the CRSwNP symptom VRS instructions, items, recall period, and response options. The five CRSwNP symptom VRS items were relevant to the majority of participants’ experience of CRSwNP. At the item level, a one-category within-person improvement was the level most frequently reported by participants to be a meaningful change. Conclusion: The CRSwNP symptom VRSs assess relevant and bothersome symptoms experienced by patients with moderate-to-severe CRSwNP, supporting content validity of this measure. The findings of this study provided preliminary insights into meaningful change in the VRS. Further quantitative assessment of meaningful change is needed, and psychometric evaluation of the CRSwNP symptom VRSs will be required to evaluate their appropriateness for assessment of clinical trial endpoints in patients with CRSwNP.
- Open Access
- 1 July 2024
- Published by National Institute for Health and Care Research in Programme Grants for Applied Research
- Vol. 12 (6) , 1-72
Collaborative care intervention for individuals with severe mental illness: the PARTNERS2 programme including complex intervention development and cluster RCT
Background and aims: Individuals living with severe mental illness such as schizophrenia and bipolar can have significant emotional, cognitive, physical and social challenges. Most people with severe mental illness in the United Kingdom do not receive specialist mental health care. Collaborative care is a system of support that combines clinical and organisational components to provide integrated and person-centred care. It has not been tested for severe mental illness in the United Kingdom. We aimed to develop and evaluate a primary care-based collaborative care model (PARTNERS) designed to improve quality of life for people with diagnoses of schizophrenia, bipolar or other psychoses when compared with usual care. Methods: Phase 1 included studies to (1) understand context: an observational retrospective study of primary and secondary care medical records and an update of the Cochrane review ‘Collaborative care approaches for people with severe mental illness’; (2) develop and formatively evaluate the PARTNERS intervention: a review of literature on collaborative care and recovery, interviews with key leaders in collaborative care and recovery, focus groups with service users and a formative evaluation of a prototype intervention model; and (3) develop trial science work in this area: a core outcome set for bipolar and recruitment methods. In phase 2 we conducted a cluster randomised controlled trial measuring quality of life using the Manchester Short Assessment of Quality of Life and secondary outcomes including time use, recovery and mental well-being; a cost-effectiveness study; and a mixed-methods process evaluation. Public involvement underpinned all of the workstream activity through the study Lived Experience Advisory Panel and the employment of service user researchers in the project team. Results phase 1: The study of records showed that care for individuals under secondary care is variable and substantial and that people are seen every 2 weeks on average. The updated Cochrane review showed that collaborative care interventions were highly variable, and no reliable conclusions can be drawn about effectiveness. The PARTNERS model incorporated change at organisational, practitioner and individual levels. Coaching was selected as the main form of support for individuals’ personal goals. In the formative evaluation, we showed that more intensive supervision and ‘top-up’ training were needed to achieve the desired shifts in practice. A core outcome set was developed for bipolar, and measures were selected for the trial. We developed a stepped approach to recruitment including initial approach and appointment. Results phase 2: The trial was conducted in four areas. In total, 198 participants were recruited from 39 practices randomised. Participants received either the PARTNERS intervention or usual care. The follow-up rate was 86% at 9–12 months. The mean change in overall Manchester Short Assessment Quality of Life score did not differ between the groups [0.25 (standard deviation 0.73) for intervention vs. 0.21 (standard deviation 0.86) for control]. We also found no difference for any secondary measures. Safety outcomes (e.g. crises) did not differ between those receiving and those not receiving the intervention. Although the costs of intervention and usual care were similar, there is insufficient evidence to draw conclusions about the overall cost-effectiveness of PARTNERS. The mixed-methods process evaluation demonstrated that a significant proportion of individuals did not receive the full intervention. This was partly due to care partner absence and participant choice. The in-depth realist informed case studies showed that participants generally appreciated the support, with some describing having a ‘professional friend’ as very important. For some people there was evidence that delivery of the intervention had led to specific personal changes. Strengths and limitations: The phase 1 records study provided insights into usual care that had not been previously documented. The realist informed complex intervention development was both theoretical and pragmatic. The trial continued through the COVID-19 pandemic with high levels of follow-up. The process evaluation had the depth to explore individual changes in participants’ response to the intervention. Weaknesses in the trial methodology included suboptimal implementation, outcome measures that may not have been sensitive to changes patients most appreciated and difficulties collecting some outcomes. Conclusions: While PARTNERS was not shown to be superior to usual care, the change to PARTNERS care was not shown to be unsafe. Full intervention implementation was challenging, but this is to be expected in studies of care that include those with psychosis. Some individuals responded well to the intervention when psychological support in the form of individualised goal setting was flexibly deployed, with evidence that having access to a ‘professional friend’ was experienced as particularly helpful for some individuals. Future work: Key components of the PARTNERS model could be developed further and tested, along with improved supervision in the context of ongoing community mental health care change. Trial registration: This trial is registered as ISRCTN95702682. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Programme Grants for Applied Research programme (NIHR award ref: NIHR200625) and is published in full in Programme Grants for Applied Research; Vol. 12, No. 6. See the NIHR Funding and Awards website for further award information.
- 1 July 2024
- Published by National Institute for Health and Care Research in Programme Grants for Applied Research
- Vol. 12 (6) , 1-72
Open AccessCollaborative care intervention for individuals with severe mental illness: the PARTNERS2 programme including complex intervention development and cluster RCT
Background and aims: Individuals living with severe mental illness such as schizophrenia and bipolar can have significant emotional, cognitive, physical and social challenges. Most people with severe mental illness in the United Kingdom do not receive specialist mental health care. Collaborative care is a system of support that combines clinical and organisational components to provide integrated and person-centred care. It has not been tested for severe mental illness in the United Kingdom. We aimed to develop and evaluate a primary care-based collaborative care model (PARTNERS) designed to improve quality of life for people with diagnoses of schizophrenia, bipolar or other psychoses when compared with usual care. Methods: Phase 1 included studies to (1) understand context: an observational retrospective study of primary and secondary care medical records and an update of the Cochrane review ‘Collaborative care approaches for people with severe mental illness’; (2) develop and formatively evaluate the PARTNERS intervention: a review of literature on collaborative care and recovery, interviews with key leaders in collaborative care and recovery, focus groups with service users and a formative evaluation of a prototype intervention model; and (3) develop trial science work in this area: a core outcome set for bipolar and recruitment methods. In phase 2 we conducted a cluster randomised controlled trial measuring quality of life using the Manchester Short Assessment of Quality of Life and secondary outcomes including time use, recovery and mental well-being; a cost-effectiveness study; and a mixed-methods process evaluation. Public involvement underpinned all of the workstream activity through the study Lived Experience Advisory Panel and the employment of service user researchers in the project team. Results phase 1: The study of records showed that care for individuals under secondary care is variable and substantial and that people are seen every 2 weeks on average. The updated Cochrane review showed that collaborative care interventions were highly variable, and no reliable conclusions can be drawn about effectiveness. The PARTNERS model incorporated change at organisational, practitioner and individual levels. Coaching was selected as the main form of support for individuals’ personal goals. In the formative evaluation, we showed that more intensive supervision and ‘top-up’ training were needed to achieve the desired shifts in practice. A core outcome set was developed for bipolar, and measures were selected for the trial. We developed a stepped approach to recruitment including initial approach and appointment. Results phase 2: The trial was conducted in four areas. In total, 198 participants were recruited from 39 practices randomised. Participants received either the PARTNERS intervention or usual care. The follow-up rate was 86% at 9–12 months. The mean change in overall Manchester Short Assessment Quality of Life score did not differ between the groups [0.25 (standard deviation 0.73) for intervention vs. 0.21 (standard deviation 0.86) for control]. We also found no difference for any secondary measures. Safety outcomes (e.g. crises) did not differ between those receiving and those not receiving the intervention. Although the costs of intervention and usual care were similar, there is insufficient evidence to draw conclusions about the overall cost-effectiveness of PARTNERS. The mixed-methods process evaluation demonstrated that a significant proportion of individuals did not receive the full intervention. This was partly due to care partner absence and participant choice. The in-depth realist informed case studies showed that participants generally appreciated the support, with some describing having a ‘professional friend’ as very important. For some people there was evidence that delivery of the intervention had led to specific personal changes. Strengths and limitations: The phase 1 records study provided insights into usual care that had not been previously documented. The realist informed complex intervention development was both theoretical and pragmatic. The trial continued through the COVID-19 pandemic with high levels of follow-up. The process evaluation had the depth to explore individual changes in participants’ response to the intervention. Weaknesses in the trial methodology included suboptimal implementation, outcome measures that may not have been sensitive to changes patients most appreciated and difficulties collecting some outcomes. Conclusions: While PARTNERS was not shown to be superior to usual care, the change to PARTNERS care was not shown to be unsafe. Full intervention implementation was challenging, but this is to be expected in studies of care that include those with psychosis. Some individuals responded well to the intervention when psychological support in the form of individualised goal setting was flexibly deployed, with evidence that having access to a ‘professional friend’ was experienced as particularly helpful for some individuals. Future work: Key components of the PARTNERS model could be developed further and tested, along with improved supervision in the context of ongoing community mental health care change. Trial registration: This trial is registered as ISRCTN95702682. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Programme Grants for Applied Research programme (NIHR award ref: NIHR200625) and is published in full in Programme Grants for Applied Research; Vol. 12, No. 6. See the NIHR Funding and Awards website for further award information.
- Open Access
- 13 September 2023
- Published by Springer Nature in Journal of Patient-Reported Outcomes
- Vol. 7 (1) , 1-11
Assessment of symptoms in COMET-ICE, a phase 2/3 study of sotrovimab for early treatment of non-hospitalized patients with COVID-19
Background: The COMET-ICE trial demonstrated that sotrovimab clinically and statistically significantly reduces the risk of all-cause > 24-h hospitalization or death due to any cause among patients with COVID-19 at high risk of disease progression. Patient-reported outcomes are important to capture symptom burden of COVID-19 and assess treatment effectiveness. This study investigated symptoms and their impact over the acute phase of COVID-19 infection among patients on sotrovimab versus placebo. Methods: Randomized (1:1), double-blind, multicenter, placebo-controlled, phase 2/3 study in 57 centers across five countries. Participants were non-hospitalized patients with symptomatic, mild-to-moderate COVID-19 and ≥ 1 baseline risk factor for disease progression (aged ≥ 55 years or ≥ 1 of the following: diabetes requiring medication, obesity, chronic kidney disease, congestive heart failure, chronic obstructive pulmonary disease, or moderate-to-severe asthma). An intravenous infusion of sotrovimab 500 mg or placebo was administered on Day 1. The FLU-PRO Plus questionnaire was administered once-daily with 24-h recall from Day 1–21, and at Day 29. Intensity and duration of COVID-19 symptoms were determined from area under the curve (AUC) and mean change in total and individual domain scores through Days 7, 14, and 21. Time to symptom alleviation was assessed. Results: In total, 1057 patients were randomized to sotrovimab (n = 528) or placebo (n = 529). At Day 7, mean decrease in FLU-PRO Plus total score (measured by AUC) was statistically significantly greater for patients on sotrovimab (–3.05 [95% confidence interval (CI) –3.27 to –2.83]) than placebo (–1.98 [95% CI –2.20 to –1.76]; difference –1.07 [95% CI –1.38 to –0.76]; p < 0.001). Significant differences were also observed at Days 14 and 21. A more rapid decline in symptom severity was observed with sotrovimab versus placebo through Week 1 and the first 21 days post-treatment. By Day 21, 41% of patients on sotrovimab and 34% on placebo reported symptom resolution. In a post-hoc analysis, median time to symptom alleviation was 4 and 6 days, respectively. Conclusions: Sotrovimab provides significant and rapid improvements in patient-reported COVID-19 symptoms, as measured by the FLU-PRO Plus. These results further show the benefits of sotrovimab in alleviating symptoms among high-risk patients with COVID-19. Trial registration ClinicalTrials.Gov: NCT04545060 (https://clinicaltrials.gov/ct2/show/NCT04545060). Date of registration: September 10, 2020 (retrospectively registered).
- 13 September 2023
- Published by Springer Nature in Journal of Patient-Reported Outcomes
- Vol. 7 (1) , 1-11
Open AccessAssessment of symptoms in COMET-ICE, a phase 2/3 study of sotrovimab for early treatment of non-hospitalized patients with COVID-19
Background: The COMET-ICE trial demonstrated that sotrovimab clinically and statistically significantly reduces the risk of all-cause > 24-h hospitalization or death due to any cause among patients with COVID-19 at high risk of disease progression. Patient-reported outcomes are important to capture symptom burden of COVID-19 and assess treatment effectiveness. This study investigated symptoms and their impact over the acute phase of COVID-19 infection among patients on sotrovimab versus placebo. Methods: Randomized (1:1), double-blind, multicenter, placebo-controlled, phase 2/3 study in 57 centers across five countries. Participants were non-hospitalized patients with symptomatic, mild-to-moderate COVID-19 and ≥ 1 baseline risk factor for disease progression (aged ≥ 55 years or ≥ 1 of the following: diabetes requiring medication, obesity, chronic kidney disease, congestive heart failure, chronic obstructive pulmonary disease, or moderate-to-severe asthma). An intravenous infusion of sotrovimab 500 mg or placebo was administered on Day 1. The FLU-PRO Plus questionnaire was administered once-daily with 24-h recall from Day 1–21, and at Day 29. Intensity and duration of COVID-19 symptoms were determined from area under the curve (AUC) and mean change in total and individual domain scores through Days 7, 14, and 21. Time to symptom alleviation was assessed. Results: In total, 1057 patients were randomized to sotrovimab (n = 528) or placebo (n = 529). At Day 7, mean decrease in FLU-PRO Plus total score (measured by AUC) was statistically significantly greater for patients on sotrovimab (–3.05 [95% confidence interval (CI) –3.27 to –2.83]) than placebo (–1.98 [95% CI –2.20 to –1.76]; difference –1.07 [95% CI –1.38 to –0.76]; p < 0.001). Significant differences were also observed at Days 14 and 21. A more rapid decline in symptom severity was observed with sotrovimab versus placebo through Week 1 and the first 21 days post-treatment. By Day 21, 41% of patients on sotrovimab and 34% on placebo reported symptom resolution. In a post-hoc analysis, median time to symptom alleviation was 4 and 6 days, respectively. Conclusions: Sotrovimab provides significant and rapid improvements in patient-reported COVID-19 symptoms, as measured by the FLU-PRO Plus. These results further show the benefits of sotrovimab in alleviating symptoms among high-risk patients with COVID-19. Trial registration ClinicalTrials.Gov: NCT04545060 (https://clinicaltrials.gov/ct2/show/NCT04545060). Date of registration: September 10, 2020 (retrospectively registered).
- Open Access
- 27 January 2023
- Published by Springer Nature in Quality of Life Research
- Vol. 32 (6) , 1645-1657
Content validity and psychometric properties of the inFLUenza Patient-Reported Outcome Plus (FLU-PRO Plus©) instrument in patients with COVID-19
Purpose: A well-defined and reliable patient-reported outcome instrument for COVID-19 is important for assessing symptom severity and supporting research studies. The InFLUenza Patient-Reported Outcome (FLU-PRO) instrument has been expanded to include loss of taste and smell in the FLU-PRO Plus, to comprehensively cover COVID-19 symptoms. Our studies were designed to evaluate and validate the FLU-PRO Plus among patients with COVID-19. Methods: Two studies were conducted: (1) a qualitative, non-interventional, cross-sectional study of patients with COVID-19 involving hybrid concept elicitation and cognitive debriefing interviews; (2) a psychometric evaluation of the measurement properties of FLU-PRO Plus, using data from COMET-ICE (COVID-19 Monoclonal antibody Efficacy Trial—Intent to Care Early). Results: In the qualitative interviews (n = 30), all 34 items of the FLU-PRO Plus were considered relevant to COVID-19, and participants determined the questionnaire was easily understood, well written, and comprehensive. In the psychometric evaluation (n = 845), the internal consistency reliability of FLU-PRO Plus total score was 0.94, ranging from 0.71 to 0.90 for domain scores. Reproducibility (Day 20–21) was 0.83 for total score, with domain scores of 0.67–0.89. Confirmatory factor analysis with the novel smell/taste domain demonstrated an acceptable fit to the data. Conclusion: The content, reliability, validity, and responsiveness of the FLU-PRO Plus in the COVID-19 population were supported. Our results suggest that FLU-PRO Plus is a content- and psychometrically-valid, fit-for-purpose measure which is easily understood by patients. FLU-PRO Plus is a suitable PRO measure for evaluating symptoms of COVID-19 and treatment benefit directly from the patient perspective. Trial Registration: ClinicalTrials.Gov: NCT04545060, September 10, 2020; retrospectively registered.
- 27 January 2023
- Published by Springer Nature in Quality of Life Research
- Vol. 32 (6) , 1645-1657
Open AccessContent validity and psychometric properties of the inFLUenza Patient-Reported Outcome Plus (FLU-PRO Plus©) instrument in patients with COVID-19
Purpose: A well-defined and reliable patient-reported outcome instrument for COVID-19 is important for assessing symptom severity and supporting research studies. The InFLUenza Patient-Reported Outcome (FLU-PRO) instrument has been expanded to include loss of taste and smell in the FLU-PRO Plus, to comprehensively cover COVID-19 symptoms. Our studies were designed to evaluate and validate the FLU-PRO Plus among patients with COVID-19. Methods: Two studies were conducted: (1) a qualitative, non-interventional, cross-sectional study of patients with COVID-19 involving hybrid concept elicitation and cognitive debriefing interviews; (2) a psychometric evaluation of the measurement properties of FLU-PRO Plus, using data from COMET-ICE (COVID-19 Monoclonal antibody Efficacy Trial—Intent to Care Early). Results: In the qualitative interviews (n = 30), all 34 items of the FLU-PRO Plus were considered relevant to COVID-19, and participants determined the questionnaire was easily understood, well written, and comprehensive. In the psychometric evaluation (n = 845), the internal consistency reliability of FLU-PRO Plus total score was 0.94, ranging from 0.71 to 0.90 for domain scores. Reproducibility (Day 20–21) was 0.83 for total score, with domain scores of 0.67–0.89. Confirmatory factor analysis with the novel smell/taste domain demonstrated an acceptable fit to the data. Conclusion: The content, reliability, validity, and responsiveness of the FLU-PRO Plus in the COVID-19 population were supported. Our results suggest that FLU-PRO Plus is a content- and psychometrically-valid, fit-for-purpose measure which is easily understood by patients. FLU-PRO Plus is a suitable PRO measure for evaluating symptoms of COVID-19 and treatment benefit directly from the patient perspective. Trial Registration: ClinicalTrials.Gov: NCT04545060, September 10, 2020; retrospectively registered.
- Open Access
- 2 September 2022
- Published by Springer Nature in Quality of Life Research
- Vol. 32 (1) , 209-223
A qualitative study to explore the symptoms and impacts of Crohn’s disease and to develop the Crohn’s Disease Diary
Purpose: To explore symptoms and disease impacts of Crohn’s disease and to develop a new patient-reported outcomes (PRO) measure according to industry best practices. Methods: A conceptual model of relevant symptoms experienced by patients with Crohn’s disease was developed following a literature review. Three rounds of combined qualitative semi-structured concept elicitation and cognitive debriefing interviews with 36 patients (≥ 16 years) with Crohn’s disease and 4 clinicians were conducted to further explore the most commonly reported and most bothersome symptoms to patients. Interview results were used to update the conceptual model as well as items and response options included in The Crohn’s Disease Diary, a new PRO measure. Results: All patients (N = 36) reported abdominal pain, loose or liquid bowel movements, and high or increased frequency of bowel movements, with most reporting these symptoms spontaneously (100%, 92%, and 75%, respectively). All patients reported bowel movement urgency, but 61% reported this symptom only when probed. Most also reported that symptoms impacted activities of daily living, work/school, and emotional, social, and physical functioning (overall, 78%–100%; spontaneously, 79% – 92%). Data regarding core symptoms of Crohn’s disease from clinician concept elicitation interviews supported patient data. The 17-item Crohn’s Disease Diary assesses core symptoms and impacts of Crohn’s disease over 24 h, and extraintestinal manifestations over 7 days. The content validity of the diary was confirmed during cognitive debriefing interviews. Conclusion: The Crohn’s Disease Diary is a new PRO measure for the assessment of Crohn’s disease symptoms and impacts, developed according to industry best practices.
- 2 September 2022
- Published by Springer Nature in Quality of Life Research
- Vol. 32 (1) , 209-223
Open AccessA qualitative study to explore the symptoms and impacts of Crohn’s disease and to develop the Crohn’s Disease Diary
Purpose: To explore symptoms and disease impacts of Crohn’s disease and to develop a new patient-reported outcomes (PRO) measure according to industry best practices. Methods: A conceptual model of relevant symptoms experienced by patients with Crohn’s disease was developed following a literature review. Three rounds of combined qualitative semi-structured concept elicitation and cognitive debriefing interviews with 36 patients (≥ 16 years) with Crohn’s disease and 4 clinicians were conducted to further explore the most commonly reported and most bothersome symptoms to patients. Interview results were used to update the conceptual model as well as items and response options included in The Crohn’s Disease Diary, a new PRO measure. Results: All patients (N = 36) reported abdominal pain, loose or liquid bowel movements, and high or increased frequency of bowel movements, with most reporting these symptoms spontaneously (100%, 92%, and 75%, respectively). All patients reported bowel movement urgency, but 61% reported this symptom only when probed. Most also reported that symptoms impacted activities of daily living, work/school, and emotional, social, and physical functioning (overall, 78%–100%; spontaneously, 79% – 92%). Data regarding core symptoms of Crohn’s disease from clinician concept elicitation interviews supported patient data. The 17-item Crohn’s Disease Diary assesses core symptoms and impacts of Crohn’s disease over 24 h, and extraintestinal manifestations over 7 days. The content validity of the diary was confirmed during cognitive debriefing interviews. Conclusion: The Crohn’s Disease Diary is a new PRO measure for the assessment of Crohn’s disease symptoms and impacts, developed according to industry best practices.